A national survey of Iranian general population to estimate a value set for the EQ-5D-5L

[1]  T. Poder,et al.  Psychometric properties of the EQ-5D-5L compared with EQ-5D-3L in cancer patients in Iran , 2022, Frontiers in Oncology.

[2]  B. Roudijk,et al.  The EQ-5D-5L Valuation Study in Egypt , 2021, PharmacoEconomics.

[3]  F. Madadizadeh,et al.  Utility Values in Colorectal Cancer Patients Treated with Chemotherapy , 2021, Cancer investigation.

[4]  Sajad Saraygord Afshari,et al.  Estimating Utility Values for Health States of DFU Patients Using EQ-5D-5L and cTTO , 2021, The international journal of lower extremity wounds.

[5]  M. Togha,et al.  Assessment of Utility in Migraine: Mapping the Migraine-Specific Questionnaire to the EQ-5D-5L. , 2021, Value in health regional issues.

[6]  C. Gudex,et al.  The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data , 2021, Applied Health Economics and Health Policy.

[7]  A. Nahvijou,et al.  Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country. , 2021, Value in health regional issues.

[8]  H. Zeraati,et al.  The impact of common chronic conditions on health-related quality of life: a general population survey in Iran using EQ-5D-5L , 2020, Cost Effectiveness and Resource Allocation.

[9]  F. Madadizadeh,et al.  Health-related quality of life and its associated factors in patients with type 2 diabetes mellitus , 2020, SAGE open medicine.

[10]  A. Nahvijou,et al.  Comparing the performance of the EQ-5D-5L with two versions of the SF-6Dv2 in patients with breast cancer , 2020, Health Services and Outcomes Research Methodology.

[11]  M. Herdman,et al.  Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines , 2020, The European Journal of Health Economics.

[12]  H. Minh,et al.  An EQ-5D-5L Value Set for Vietnam , 2020, Quality of Life Research.

[13]  M. Soofi,et al.  Interim value set for the EQ-5D-5L in Iran using the Crosswalk method , 2020, Medical journal of the Islamic Republic of Iran.

[14]  Elly Stolk,et al.  Valuing Health State: An EQ-5D-5L Value Set for Ethiopians. , 2020, Value in health regional issues.

[15]  A. Akbari Sari,et al.  Assessing the performance of direct and indirect utility eliciting methods in patients with colorectal cancer: EQ-5D-5L versus C-TTO , 2019, Health Services and Outcomes Research Methodology.

[16]  Clare Evans,et al.  Associations Between Physical Function and Subjective Well-Being in Older Adults From Low- and Middle-Income Countries: Results From the Study on Global AGEing and Adult Health (SAGE). , 2019, Journal of aging and physical activity.

[17]  Elly Stolk,et al.  Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  Chia-Ing Li,et al.  Valuation of the EQ-5D-5L in Taiwan , 2018, PloS one.

[19]  Juan Manuel Ramos-Goñi,et al.  The EQ-5D-5L Valuation study in Thailand , 2018, Expert review of pharmacoeconomics & outcomes research.

[20]  Thomas Kohlmann,et al.  A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D , 2018, PharmacoEconomics.

[21]  Kristina Ludwig,et al.  German Value Set for the EQ-5D-5L , 2018, PharmacoEconomics.

[22]  Jan Passchier,et al.  The Indonesian EQ-5D-5L Value Set , 2017, PharmacoEconomics.

[23]  Nan Luo,et al.  Estimating an EQ-5D-5L Value Set for China. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  Mark Oppe,et al.  Quality Control Process for EQ-5D-5L Valuation Studies. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  Mark Oppe,et al.  Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid Approach , 2014, Medical care.

[26]  Takashi Fukuda,et al.  Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  G Ardine de Wit,et al.  Dutch Tariff for the Five-Level Version of EQ-5D. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  Mark Oppe,et al.  EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes , 2016, PharmacoEconomics.

[29]  N. Bansback,et al.  A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada , 2015, Medical care.

[30]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[31]  Mark Oppe,et al.  A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[33]  M. Weinstein,et al.  QALYs: the basics. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  N. Ikegami,et al.  Estimating an EQ-5D population value set: the case of Japan. , 2002, Health economics.

[35]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[36]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[37]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.